$0.21
-0.55 (-71.86%)
Open$0.48
Previous Close$0.76
Day High$0.48
Day Low$0.20
52W High$5.14
52W Low$0.43
Volume—
Avg Volume1.39M
Market Cap25.30M
P/E Ratio—
EPS$-1.85
SectorBiotechnology
Analyst Ratings
Sell
10 analysts
Price Target
+23,027.6% upside
Current
$0.21
$0.21
Target
$49.47
$49.47
$36.23
$49.47 avg
$53.77
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 1.20M | 848.4K | 9.03M |
| Net Income | -65,965,628 | -80,993,442 | 1.99M |
| Profit Margin | -5,491.3% | -10,050.9% | 22.0% |
| EBITDA | -68,084,832 | -92,813,868 | 3.04M |
| Free Cash Flow | — | — | 1.40M |
| Rev Growth | — | -24.1% | +1.4% |
| Debt/Equity | 0.00 | — | 0.61 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $251.53 | -1.09% | 118.2 | 429.58B |
| AMGN | Amgen Inc | $361.16 | +0.17% | 24.8 | 193.10B |
| GILD | Gilead Sciences Inc | $126.13 | -0.16% | 17.1 | 157.21B |
| VRTX | Vertex Pharmaceuticals Inc | $494.74 | -0.98% | 28.1 | 121.87B |
| REGN | Regeneron Pharmaceuticals | $628.06 | -0.59% | 15.0 | 66.35B |
| ALNY | Alnylam Pharmaceuticals Inc | $297.43 | +1.33% | 69.3 | 39.97B |